Want to see JP:2664 full AI Analyst Report?
Top Page
Cawachi Limited
(2664)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥3,775.00
▲(4.28% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by stable financial footing (low leverage and consistently positive operating cash flow) but constrained by flat-to-down revenue and thin profitability with a latest-year earnings decline. Technicals are a meaningful positive with price above key moving averages and neutral-to-positive momentum. Valuation is balanced: a ~3.0% dividend yield helps, while a ~22.8 P/E limits upside relative to recent earnings performance.
Positive Factors
Conservative balance sheet
Low leverage and sizeable equity provide financial resilience and long-term optionality. A debt-to-equity near 0.15 and modest absolute debt limits refinancing risk, preserves borrowing capacity for strategic investments, and helps the company withstand cyclical retail shocks without forcing asset sales.
Negative Factors
Flat-to-declining revenue trend
Persistent flat or slightly negative top-line growth constrains scale benefits and long-term earnings expansion. Without sustained revenue growth, investment in new formats, technology or store refreshes must compete with near-term cash needs, limiting the company’s ability to broaden market share.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and sizeable equity provide financial resilience and long-term optionality. A debt-to-equity near 0.15 and modest absolute debt limits refinancing risk, preserves borrowing capacity for strategic investments, and helps the company withstand cyclical retail shocks without forcing asset sales.
Read all positive factors
Cawachi Limited (2664) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥83.59B
Dividend Yield2.67%
Average Volume (3M)35.49K
Price to Earnings (P/E)25.7
Beta (1Y)0.29
Revenue Growth-0.72%
EPS Growth-31.42%
CountryJP
Employees2,750
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)145.82
Shares Outstanding24,583,420
10 Day Avg. Volume30,120
30 Day Avg. Volume35,490
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.58
Price to Sales (P/S)0.23
P/FCF Ratio14.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cawachi Limited Business Overview & Revenue Model
Company Description
Cawachi Limited manages drugstores in Japan. It is involved in retail and insurance dispensing of medicines, medical-related products, health foods, childcare products, cosmetics, daily necessities, general foods, confectionery. The company was fo...
How the Company Makes Money
null...
Cawachi Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 285.45B | 284.49B | 287.82B | 285.96B | 281.87B | 279.46B |
| Gross Profit | 65.46B | 65.26B | 66.66B | 65.80B | 64.05B | 63.15B |
| EBITDA | 11.82B | 11.20B | 11.36B | 11.49B | 10.90B | 12.16B |
| Net Income | 3.26B | 3.20B | 4.88B | 4.71B | 4.18B | 4.83B |
Balance Sheet | ||||||
| Total Assets | 202.55B | 199.61B | 200.96B | 197.24B | 195.24B | 192.48B |
| Cash, Cash Equivalents and Short-Term Investments | 44.63B | 38.11B | 36.67B | 35.62B | 38.45B | 38.96B |
| Total Debt | 16.51B | 16.11B | 16.60B | 16.73B | 19.55B | 22.92B |
| Total Liabilities | 87.71B | 83.68B | 86.55B | 85.94B | 87.51B | 87.83B |
| Stockholders Equity | 114.83B | 115.93B | 114.41B | 111.30B | 107.72B | 104.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.66B | 3.40B | 1.02B | 4.11B | 2.37B |
| Operating Cash Flow | 0.00 | 8.87B | 7.48B | 6.40B | 9.82B | 6.87B |
| Investing Cash Flow | 0.00 | -5.16B | -4.51B | -5.29B | -5.84B | -4.54B |
| Financing Cash Flow | 0.00 | -2.27B | -1.92B | -3.94B | -4.49B | -4.61B |
Cawachi Limited Technical Analysis
Positive
3620.00
Price Trends
3520.10
Positive
3317.26
Positive
3133.79
Positive
Market Momentum
91.19
Positive
61.65
Neutral
30.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2664, the sentiment is Positive. The current price of 3620 is below the 20-day moving average (MA) of 3649.25, above the 50-day MA of 3520.10, and above the 200-day MA of 3133.79, indicating a bullish trend. The MACD of 91.19 indicates Positive momentum. The RSI at 61.65 is Neutral, neither overbought nor oversold. The STOCH value of 30.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2664.
Cawachi Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥438.35B | 13.77 | 11.29% | 3.42% | 4.32% | 0.18% | |
67 Neutral | ¥264.21B | 15.81 | 10.75% | 1.20% | 12.20% | -25.42% | |
66 Neutral | ¥83.59B | 25.68 | ― | 3.01% | -0.72% | -31.42% | |
64 Neutral | ¥1.08T | 18.49 | 7.67% | 2.04% | ― | ― | |
64 Neutral | ¥523.53B | 16.25 | ― | 1.28% | 8.72% | 3.45% | |
64 Neutral | ¥399.48B | 23.11 | ― | 0.41% | 13.04% | -0.05% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
JP:2664
Cawachi Limited
3,745.00
1,031.16
38.00%
JP:9989
Sundrug Co
3,723.00
-761.84
-16.99%
JP:7649
Sugi Holdings Co
1,339.00
-507.61
-27.49%
JP:3391
TSURUHA Holdings
2,378.50
125.68
5.58%
JP:3349
COSMOS Pharmaceutical Corporation
6,569.00
-2,224.76
-25.30%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,097.00
240.64
6.24%
Cawachi Limited Corporate Events
Cawachi Launches ¥2 Billion Share Buyback to Boost Shareholder Returns
Aug 3, 2026
Cawachi Limited’s board has approved a share buyback program authorizing the repurchase of up to 700,000 common shares, representing about 3.13% of outstanding stock, at a total cost of up to ¥2 billion. The buyback will run from August...
Cawachi Delivers Profit Growth in Q1 but Guides for Weaker Margins
Jul 29, 2026
Cawachi Limited reported a modest year-on-year increase in net sales to ¥71,981 million for the quarter ended June 15, 2026, with operating profit climbing 15.9% and profit attributable to owners of parent rising 5.5%. Earnings per share impr...
Cawachi Limited Profits Slump but Dividend Raised on 65th Anniversary
May 11, 2026
Cawachi Limited reported a slight 1.2% decline in net sales to ¥284.5 billion for the fiscal year ended March 15, 2026, with operating profit down 9.1% and profit attributable to owners of the parent dropping 34.5% to ¥3.2 billion, refle...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.